NasdaqGM - Delayed Quote USD

Alpine Immune Sciences, Inc. (ALPN)

64.62 +0.05 (+0.08%)
At close: April 25 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
58,876.00
58,876.00
30,064.00
23,443.00
9,335.00
Operating Expense
103,126.00
103,126.00
88,211.00
73,302.00
38,084.00
Operating Income
-44,250.00
-44,250.00
-58,147.00
-49,859.00
-28,749.00
Net Non Operating Interest Income Expense
11,754.00
11,754.00
2,812.00
-557.00
-530.00
Other Income Expense
415.00
415.00
-97.00
-4.00
1,333.00
Pretax Income
-32,081.00
-32,081.00
-55,432.00
-50,420.00
-27,946.00
Tax Provision
103.00
103.00
2,330.00
-87.00
-6.00
Net Income Common Stockholders
-32,184.00
-32,184.00
-57,762.00
-50,333.00
-27,940.00
Diluted NI Available to Com Stockholders
-32,184.00
-32,184.00
-57,762.00
-50,333.00
-27,940.00
Basic EPS
-1.29
-0.64
-1.73
-1.98
-1.34
Diluted EPS
-1.29
-0.64
-1.73
-1.98
-1.34
Basic Average Shares
45,980.02
50,000.34
33,435.28
25,476.89
20,826.47
Diluted Average Shares
45,980.02
50,000.34
33,435.28
25,476.89
20,826.47
Total Operating Income as Reported
-44,250.00
-44,250.00
-58,147.00
-49,859.00
-28,749.00
Total Expenses
103,126.00
103,126.00
88,211.00
73,302.00
38,084.00
Net Income from Continuing & Discontinued Operation
-32,184.00
-32,184.00
-57,762.00
-50,333.00
-27,940.00
Normalized Income
-32,184.00
-32,184.00
-57,762.00
-50,333.00
-27,940.00
Interest Income
11,852.00
11,852.00
3,288.00
259.00
245.00
Interest Expense
98.00
98.00
476.00
816.00
775.00
Net Interest Income
11,754.00
11,754.00
2,812.00
-557.00
-530.00
EBIT
-31,983.00
-31,983.00
-54,956.00
-49,604.00
-27,171.00
EBITDA
-31,407.00
-31,407.00
-54,359.00
-48,984.00
-26,593.00
Reconciled Depreciation
576.00
576.00
597.00
620.00
578.00
Net Income from Continuing Operation Net Minority Interest
-32,184.00
-32,184.00
-57,762.00
-50,333.00
-27,940.00
Normalized EBITDA
-31,407.00
-31,407.00
-54,359.00
-48,984.00
-26,593.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 6/17/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VERA Vera Therapeutics, Inc.
38.69
-3.15%
 
JANX Janux Therapeutics, Inc.
47.10
-2.30%
 
MOR MorphoSys AG
18.13
+0.44%
 
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
 
RVMD Revolution Medicines, Inc.
35.33
-0.73%
 
BHVN Biohaven Ltd.
38.54
-0.46%
 
CRNX Crinetics Pharmaceuticals, Inc.
42.29
-2.38%
 
ENTX Entera Bio Ltd.
2.0000
-3.38%
 
DYN Dyne Therapeutics, Inc.
23.70
-5.14%
 
IBRX ImmunityBio, Inc.
5.11
+6.02%